SCHEMBL718951

SCHEMBL718951

C#Cc1cc(Cl)cc(Cl)c1

nearest known ligand 0.50

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.50
CYP3A4 P08684 2/20 0.38
TP53 P04637 1/20 0.38
CYP1A1 P04798 1/20 0.37
CYP1B1 Q16678 1/20 0.37
HDAC8 Q9BY41 2/20 0.33
ALDH1A1 P00352 2/20 0.33
TPMT P51580 1/20 0.32
RECQL P46063 1/20 0.30
HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11226509 0.85 TSHR (0.36) TSHRCYP1A1CYP1B1
SCHEMBL13982141 0.82 RAPGEF4 (0.33) TSHRCYP1A1CYP1B1HDAC8
SCHEMBL15094220 0.82 RAPGEF4 (0.32) TSHRCYP1A1CYP1B1
SCHEMBL4391765 0.82 GRM5 (0.37)
SCHEMBL7034739 0.82 HCAR1 (0.40) TSHRCYP3A4CYP1A1CYP1B1ALDH1A1
SCHEMBL8486211 0.82 CYP3A4 (0.55) TSHRCYP3A4TP53CYP1A1CYP1B1
SCHEMBL11230096 0.82 TSHR (0.33) TSHR
SCHEMBL11237065 0.80 GAA (0.35) TSHRALDH1A1
SCHEMBL24216635 0.77 HSD17B10 (0.38) ALDH1A1HSD17B10
SCHEMBL30460212 0.77 HSD17B10 (0.38) ALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111808071-A Method for synthesizing polysubstituted aminoisoquinoline compound by cyclization of pyridine and alkyne under catalysis of rhodium 中国科学院兰州化学物理研究所 2020-10-23 CN claimed
EP-2861566-B1 NEW DIAZASPIROCYCLOALKANE AND AZASPIROCYCLOALKANE HOFFMANN LA ROCHE (CH) 2016-12-21 EP claimed
EP-1664027-B1 SUBSTITUTED 2,3-DIHYDRO-1H-ISOINDOL-1-ONE DERIVATIVES AND METHODS OF USE AMGEN INC (US) 2009-12-30 EP claimed
EP-1664023-B1 SUSTITUTED ISOQUINOLINE DERIVATIVES AND METHODS OF USE AMGEN INC (US) 2008-08-13 EP claimed
EP-1310487-B1 PROCESSES FOR PREPARATION OF BICYCLIC COMPOUNDS AND INTERMEDIATES THEREFOR DAIICHI SEIYAKU CO (JP) 2007-01-03 EP claimed
EP-0771196-B1 EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS LILLY CO ELI (US) 1999-12-08 EP claimed
US-20250115630-A1 METAL COMPLEXES UDC IRELAND LTD (IE) 2025-04-10 US disclosed
US-12180233-B2 Metal complexes UDC IRELAND LIMITED (IE) 2024-12-31 US disclosed
CN-111699192-B Metal complex UDC爱尔兰有限公司 2024-03-08 CN disclosed
EP-3752512-B1 METAL COMPLEXES MERCK PATENT GMBH (DE) 2023-03-01 EP disclosed
US-20220289778-A1 METAL COMPLEXES UDC IRELAND LIMITED (IE) 2022-09-15 US disclosed
CN-111808071-B Method for synthesizing polysubstituted aminoisoquinoline compound by cyclization of pyridine and alkyne under catalysis of rhodium 中国科学院兰州化学物理研究所 2022-03-25 CN disclosed
EP-3752512-A1 METAL COMPLEXES Merck Patent GmbH (DE) 2020-12-23 EP disclosed
EP-0171209-B1 ACETYLENIC PHENOXYPROPANOL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION McNeilab, Inc. (US) 1989-03-01 EP disclosed
US-4742084-A Aralykyl (arylethynyl)aralkyl amines and their use as vasodilators and antihypertensives MCNEILAB, INC. (US) 1988-05-03 US disclosed
US-4661635-A ANTIARRHYTHMIA AGENTS MCNEILAB, INC. (US) 1987-04-28 US disclosed
US-4652584-A Acetylenic phenoxypropanol derivatives and pharmaceutical compositions for the treatment of hypertension MCNEILAB, INC. (US) 1987-03-24 US disclosed
EP-0171209-A1 Acetylenic phenoxypropanol derivatives and pharmaceutical compositions for the treatment of hypertension McNeilab, Inc. (US) 1986-02-12 EP disclosed
EP-0146271-A2 Aralykyl (arylethynyl) aralkyl amines for use as vasodilators and antihypertensives McNeilab, Inc. (US) 1985-06-26 EP disclosed
EP-0145361-A2 Acetylene derivatives for the treatment of hypertension and angina McNeilab, Inc. (US) 1985-06-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12180233-B2 Metal complexes IMMT, MCU, SOD1 TSHR 3493/4885CYP3A4 2260/4885TP53 3881/4885
US-20250115630-A1 METAL COMPLEXES IMMT, MCU, SOD1 TSHR 3493/4885CYP3A4 2260/4885TP53 3881/4885
US-20220289778-A1 METAL COMPLEXES IMMT, MCU, SOD1 TSHR 3493/4885CYP3A4 2260/4885TP53 3881/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.